88 related articles for article (PubMed ID: 22286641)
1. Switching between anti-TNF-alpha agents does not improve functional capacity in patients with long-standing and active rheumatoid arthritis.
Soares MR; Reis Neto ET; Luz KR; Ciconelli RM; Pinheiro MM
Rev Bras Reumatol; 2012; 52(1):9-15. PubMed ID: 22286641
[TBL] [Abstract][Full Text] [Related]
2. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study.
Gomez-Reino JJ; Maneiro JR; Ruiz J; Roselló R; Sanmarti R; Romero AB;
Ann Rheum Dis; 2012 Nov; 71(11):1861-4. PubMed ID: 22736086
[TBL] [Abstract][Full Text] [Related]
5. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
8. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
[TBL] [Abstract][Full Text] [Related]
9. Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers.
Abhishek A; Butt S; Gadsby K; Zhang W; Deighton CM
J Clin Rheumatol; 2010 Jan; 16(1):15-8. PubMed ID: 20051749
[TBL] [Abstract][Full Text] [Related]
10. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
[TBL] [Abstract][Full Text] [Related]
11. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability.
Tanaka E; Mannalithara A; Inoue E; Hara M; Tomatsu T; Kamatani N; Singh G; Yamanaka H
Ann Rheum Dis; 2008 Aug; 67(8):1153-8. PubMed ID: 17971459
[TBL] [Abstract][Full Text] [Related]
12. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
[TBL] [Abstract][Full Text] [Related]
13. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML
Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467
[TBL] [Abstract][Full Text] [Related]
14. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
Jois RN; Masding A; Somerville M; Gaffney K; Scott DG
Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180
[TBL] [Abstract][Full Text] [Related]
15. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
Metsios GS; Stavropoulos-Kalinoglou A; Douglas KM; Koutedakis Y; Nevill AM; Panoulas VF; Kita M; Kitas GD
Rheumatology (Oxford); 2007 Dec; 46(12):1824-7. PubMed ID: 18032540
[TBL] [Abstract][Full Text] [Related]
16. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
[TBL] [Abstract][Full Text] [Related]
17. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
[TBL] [Abstract][Full Text] [Related]
18. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
El Miedany Y; Youssef SS; El Gaafary M
J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
[TBL] [Abstract][Full Text] [Related]
19. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis.
Mattey DL; Brownfield A; Dawes PT
J Rheumatol; 2009 Jun; 36(6):1180-7. PubMed ID: 19447930
[TBL] [Abstract][Full Text] [Related]
20. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]